Novo Nordisk semaglutide phase 3 trial for MASH meets primary endpoints

Mohammed Haneefa Nizamudeen A phase 3 trial examining Novo Nordisk's ( NVO ) GLP-1 medicine semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) met its primary endpoints. Those endpoints were significant improvement in liver fibrosis with no worsening of steatohepatitis, and no worsening of liver.